Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

The American Society for Preventive Cardiology (ASPC) recently announced that they will be accepting applications for the position of Editor-in-Chief for the American Journal of Preventive Cardiology ...

Lynnette A. Clinton, who served as vice president of applications in BayCare Health System's information services (IS) department until last December, has returned to the health system as chief ...

Fleet Street legend and Mirror columnist, Paul Routledge, sends gentle tales from his West Yorkshire allotment, Mrs R’s ...

Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...